According to the results of AstraZeneca’s US clinical study, the Covid-19 vaccine has a 74 percent efficacy in preventing symptomatic illness, with an increase to 83.5 percent in those aged 65 and older.
According to Reuters, the study looked at nearly 26,000 volunteers in the United States, Chile, and Peru who received two vaccine doses about a month apart.
“I was pleasantly surprised,” Dr. Anna Durbin, a vaccination researcher at Johns Hopkins University and one of the study’s scientists, said of the overall finding.
The researcher says that was enough to prevent major illnesses and hospitalizations
Among the more than 17,600 people who received the vaccination, there were no cases of severe or serious symptomatic Covid-19. In comparison, there were just eight cases of this type among the 8,500 volunteers who received the placebo. There were two deaths in the placebo group, but none in the vaccination group. There were also no occurrences of thrombosis with thrombocytopenia, an uncommon blood clotting side effect connected to the AstraZeneca vaccination.
The findings were reported in the New England Journal of Medicine.